Scientific Advisory Board

 

Comprised of highly distinguished academic scientists with extensive experience in the biotechnology industry; the Bio-Techne Scientific Advisory Board provides an objective, external perspective on the company's technology platforms and scientific directions. This board helps ensure that Bio-Techne will continue to be an innovative leader in the Life Sciences field.

The Scientific Advisory Board includes three current scientist members of the Board of Directors, along with three academic leaders. Collectively, they provide a broad range of expertise over several new areas of biomedical science, in particular within the protein and antibody field. They also cultivate expertise in cutting-edge methodology and the latest discovery tools. This board interacts with and advises Bio-Techne scientists, through both formal review sessions and informal, regular contacts, visits and ad hoc discussions.
 

Roger C. Lucas, Ph.D.

Vice Chairman, Board of Directors Bio-Techne Corporation
 

Dr. Lucas has had a relationship with Bio-Techne since its inception, serving as vice president of research, chief scientific officer, and founder of the Biotechnology Division. He holds a Ph.D. in physiology and cell biology from the Illinois Institute of Technology.

 

Charles A. Dinarello, M.D.

Professor of Medicine, University of Colorado School of Medicine
 

Distinguished Professor of Medicine and Immunology at the University of Colorado Medical Center at Denver, Dr. Dinarello is a member of the National Academy of Sciences and one of the founders of the cytokine field of research.

 

Roeland Nusse, Ph.D.

Chair of the Department of Developmental Biology, Stanford University
 

Professor and past Chairman of the Department of Developmental Biology at Stanford University, Dr. Nusse is a member of both the Institute for Stem Cell Biology and Regenerative Medicine and the National Academy of Sciences. He is also an investigator with the Howard Hughes Medical Institute.

 

David Artis, Ph.D.

Director, Roberts Institute for Research in Inflammatory Bowel Disease, Weill Cornell Medical College
 

Dr. Artis recently was appointed the founding Director of the Roberts Institute for Research in IBD at Weill Cornell Medical College. Prior to that, Dr. Artis was Associate Professor in Microbiology at the University of Pennsylvania Perelman School of Medicine, and Program Director of Inflammation for the Penn Institute of Immunology. Dr. Artis' research focuses on the body's immune system, how it fights infection and how its normal function can become dysregulated, leading to the development of chronic inflammatory diseases including psoriasis, arthritis and inflammatory bowel disease.

 

John M. Denu, Ph.D.

Professor in Biomolecular Chemistry, University of Wisconsin, Madison.
 

In addition to his faculty position with the Biomolecular Chemistry department at the University of Wisconsin - Madison, Dr. Denu was also appointed several years ago as the Epigenetics Theme Leader at the Wisconsin Institutes of Discovery, which explores key areas of scientific inquiry with a cross-disciplinary focus. Dr. Denu's current focus is understanding the molecular mechanisms of epigenetic regulators, and their impact on physiology (particularly on stem cell biology and metabolism.

 

Sachdev Sidhu, Ph.D.

Professor, Donnelly Centre for Cellular & Biomolecular Research, University of Toronto
 

In addition to his position as Professor with the Donnelly Centre for Cellular and Biomolecular Research, Dr. Sidhu is also a Senior Investigator at the Ontario Institute for Cancer Research, Department of Protein Engineering, at the University of Toronto. Building on his antibody expertise honed earlier as a scientist at Genentech in California, Dr. Sidhu also established the cutting-edge Toronto Recombinant Antibody Centre (TRAC) at the University of Toronto. Dr. Sidhu's research is primarily focused in the field of protein engineering and technologies that explore and shape protein and antibody structure and function, with the aim of crafting better therapies for cancer, diabetes and other diseases.